Pharmaceutical Technology8 天
Lenvatinib mesylate by Eisai for Gastric Cancer: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III drugs for Gastric Cancer have a 46% phase transition ...
Pharmaceutical Technology8 天
Lenvatinib mesylate by Eisai for Epithelial Ovarian Cancer: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase I for Epithelial Ovarian Cancer.